(0.25%) 5 112.60 points
(0.20%) 38 317 points
(0.26%) 15 969 points
(-1.34%) $82.73
(3.90%) $1.998
(0.07%) $2 348.80
(-0.30%) $27.45
(3.56%) $954.95
(-0.18%) $0.933
(-0.32%) $10.99
(-0.47%) $0.797
(1.74%) $93.47
@ $22.05
发出时间: 15 Feb 2024 @ 04:38
回报率: -3.58%
上一信号: Feb 14 - 04:50
上一信号:
回报率: 4.26 %
Live Chart Being Loaded With Signals
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML); and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD)...
Stats | |
---|---|
今日成交量 | 73 755.00 |
平均成交量 | 1.10M |
市值 | 1.81B |
EPS | $0 ( 2024-02-27 ) |
下一个收益日期 | ( $0 ) 2024-05-06 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -7.13 |
ATR14 | $0.0220 (0.10%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-02-07 | Metzger Michael A | Buy | 214 500 | Stock Options (Right to buy) |
2024-02-07 | Metzger Michael A | Buy | 39 000 | Common Stock |
2024-02-07 | Metzger Michael A | Buy | 107 250 | Common Stock |
2024-02-07 | Goldan Keith A. | Buy | 70 000 | Stock Options (Right to buy) |
2024-02-07 | Goldan Keith A. | Buy | 11 700 | Common Stock |
INSIDER POWER |
---|
46.03 |
Last 97 transactions |
Buy: 2 711 593 | Sell: 1 085 664 |
音量 相关性
Syndax Pharmaceuticals 相关性 - 货币/商品
Syndax Pharmaceuticals 财务报表
Annual | 2023 |
营收: | $0 |
毛利润: | $-12 000.00 (0.00 %) |
EPS: | $-2.98 |
FY | 2023 |
营收: | $0 |
毛利润: | $-12 000.00 (0.00 %) |
EPS: | $-2.98 |
FY | 2022 |
营收: | $0 |
毛利润: | $-454 000 (0.00 %) |
EPS: | $-2.37 |
FY | 2021 |
营收: | $139.71M |
毛利润: | $0.00 (0.00 %) |
EPS: | $0.480 |
Financial Reports:
No articles found.
Syndax Pharmaceuticals
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML); and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD). The company is also developing Entinostat. It also has collaborative research and development agreement with National Cancer Institute; a clinical trial agreement with Eastern Cooperative Oncology Group; and a license agreement with Kyowa Hakko Kirin Co., Ltd. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.Massachusetts.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。